A Case of Fulminant Meningococcemia: It Is All in the Complement

Eculizumab is a novel monoclonal antibody that inhibits complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Complement deficiency is a well-known risk factor for meningococcal infection. We describe a case of a young patient with PNH treated with eculizumab who...

Full description

Saved in:
Bibliographic Details
Main Authors: Kellie L. Hawkins, Mariah Hoffman, Sonia Okuyama, Sarah E. Rowan
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Case Reports in Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2017/6093695
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eculizumab is a novel monoclonal antibody that inhibits complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Complement deficiency is a well-known risk factor for meningococcal infection. We describe a case of a young patient with PNH treated with eculizumab who presented with a life-threatening case of nongroupable meningococcemia. As this new biologic agent becomes more widely prescribed, providers should be aware of the increased risk of meningococcemia. In addition to vaccination, providers may consider the use of oral penicillin for antibiotic prophylaxis against Neisseria meningitidis in these cases of functional complement deficiency.
ISSN:2090-6625
2090-6633